{
Poseida Therapeutics, Inc.

Companies

}
Symbol PSTX
Name Poseida Therapeutics, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State CA
City San Diego
Zipcode 92121
Website http://www.poseida.com
Track all markets on TradingView
roche's unexpected acquisition of poseida therapeutics for one billion dollars
Roche's decision to acquire Poseida Therapeutics for $1 billion upfront came after initial reluctance, as filings reveal that partner Astellas did not submit an offer. Prior to Roche's announcement, another undisclosed pharmaceutical company had expressed interest in Poseida's cell therapy assets.
Endpoints News
Poseida Therapeutics, Inc. Hoffmann-La Roche AG Astellas Pharma Inc. Show more
Finance & Economy, News Article
15:24 10.12.2024
roche initiates takeover bid for poseida therapeutics at nine dollars per share
Roche has initiated a tender offer for all outstanding common shares of Poseida Therapeutics at nine dollars per share in cash, along with a contingent value right (CVR) for potential additional payments of up to four dollars per share. The offer will expire on January 7, pending regulatory approvals and the valid tender of a majority of shares.
MarketScreener
United States Dollar Poseida Therapeutics, Inc. Hoffmann-La Roche AG
Finance & Economy, Press Release
07:48 10.12.2024
Roche launches tender offer for Poseida shares at nine dollars each
Roche has initiated a tender offer for all outstanding shares of Poseida Therapeutics at $9.00 per share in cash, along with a contingent value right for potential additional payments of up to $4.00 per share. This offer follows a merger agreement dated November 25, 2024, and will expire on January 7, 2025, unless extended. Roche has filed the necessary documentation with the United States Securities and Exchange Commission.
TipRanks Financial
United States Dollar Roche Holding AG Poseida Therapeutics, Inc. CHE
Finance & Economy, Press Release
22:35 09.12.2024
roche initiates tender offer for poseida therapeutics at nine dollars per share
[SEC]
GlobeNewswire News Room
Poseida Therapeutics, Inc. Hoffmann-La Roche AG Chugai Pharmaceutical Co., Ltd. Genentech USA JPN CHE Show more
Healthcare, Press Release
22:30 09.12.2024
roche to acquire poseida for car t cell therapy development
Roche plans to acquire Poseida Therapeutics for $1.5 billion, focusing on allogeneic CAR-T cell therapies, including the investigational dual CAR-T therapy P-CD19CD20-ALLO1, currently in phase 1 trials for B-cell malignancies. The acquisition aims to enhance development in oncology, immunology, and neurology, with potential applications for multiple sclerosis and systemic lupus erythematosus. The deal is expected to close in Q1 2025.
Managed Healthcare Executive
United States Dollar Poseida Therapeutics, Inc. Hoffmann-La Roche AG USA Levi Garraway
Healthcare, Press Release
22:08 09.12.2024
Roche advances subcutaneous Lunsumio in lymphoma amid competitive CAR-T landscape
Roche's subcutaneous Lunsumio has shown comparable efficacy to its intravenous version in treating follicular lymphoma, with an overall response rate of 76.6% versus 81.1% for IV. The new formulation offers advantages in administration time and safety, with lower rates of adverse events and cytokine release syndrome. Roche is also advancing its bispecific therapies, including trials for Lunsumio in combination with other treatments for diffuse large B-cell lymphoma.
Fierce Pharma
Poseida Therapeutics, Inc. Hoffmann-La Roche AG ABBVIE Genmab A/S Genentech Charlie Fuchs Show more
Healthcare, Market Report
21:16 09.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.